Merck Sharp & Dohme is the UK subsidiary of American pharmaceutical manufacturer Merck. The company markets such Merck products as arthritis pain treatment Arcoxia (which is approved in Europe but not the US), high blood pressure medication Cozaar, osteoporosis drug Fosamax, and asthma treatment Singulair. It also operates its parent's largest manufacturing facility outside the US, making about 20 medicines at its Cramlington, Northumberland, plant. Its Hoddesdon headquarters handles sales, marketing, and administrative functions; it also includes an R&D center that runs clinical trials and performs research and development activities specializing in organic and synthetic chemistry.

Insmed Incorporated Company was founded in 1999 and is headquartered in Richmond, Virginia. Insmed Incorporated, a development stage company, engages in the development of recombinant protein drug. The company's primary product includes IPLEX, a complex of recombinant human IGF-1 and its binding protein IGFBP-3 for use in the treatment of several serious medical conditions, as well as conducting a phase III enabling clinical trial for investigating IPLEX as a treatment for myotonic muscular dystrophy. Insmed also engages in various oncology programs, including INSM-18, an orally available small molecule tyrosine kinase inhibitor that has demonstrated selective inhibition of IGF-1 and human epidermal growth factor receptor; and rhIGFBP-3, which is in early clinical development stage for the treatment of breast, prostate, liver, ovarian, and colon cancers. The company also provides Expanded Access Program in Italy to offer IPLEX to physicians for use in their patients with amyotrophic lateral sclerosis. It has a license to Pharmacia AB's portfolio of regulatory filings pertaining to rhIGF; and an agreement with NAPO Pharmaceuticals that gives NAPO the right to develop, manufacture, and commercialize masoprocal products for various indications relating to diabetes, cardiac disease, vascular disease, metabolic disease, and syndrome X.

Chimerix, Inc. company was founded in 2002 and is headquartered in Durham, North Carolina. Chimerix has developed technology to make molecules with therapeutic potential into oral drugs. Its lipid conjugate technology can modify drug compounds to mimic a particular lipid metabolite that is absorbed by the small intestine, thus protecting the compounds from being broken down in the stomach. Chimerix is using its technology to develop lead drug candidate CMX001 to fight smallpox infections or bad reactions to smallpox vaccinations. The development-stage firm is also targeting drug-resistant HIV and hepatitis.

Nabi Biopharmaceuticals company was founded in 1967 and is headquartered in Rockville, Maryland. Nabi Biopharmaceuticals, a biopharmaceutical company, develops products that address unmet medical needs in the areas of nicotine addiction and infectious disease in the United States. The company is developing NicVAX, a proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse. It has a manufacturing services agreement with Biotest Pharmaceuticals Corporation, which enables it to obtain clinical lots of its retained products, as well as component products from Biotest. Nabi Biopharmaceuticals also has license and royalty agreements with National Institute of Allergy and Infectious Diseases; National Institute for Drug Abuse; Department of Defense; National Institutes of Health; and University of Maryland.

Dako makes disease diagnosis a little more clear-cut. A leader in the area of pathology testing, Dako makes instrumentation systems, reagents, and software used by pathology laboratories to analyze human tissues for the presence of cancer. Its Automated Link line of pathology instruments include staining and visualization systems, chemical and antibody reagents, and Dako Link workflow management software. The company also makes reagents used in flow cytometry testing (which analyzes the cells in blood) and in clinical immunochemistry (which measures proteins in body fluids). The company was acquired by private equity fund EQT in 2007 and subsequently divested its flow cytometry instrumentation business.

QuA Vodis aims to help biotechnology and pharmaceutical companies get where they are going. The company, whose name shouldn't be confused with the movie Quo Vadis, offers interim management, quality assurance system development and training, and regulatory assistance to firms engaged in human and veterinary medical research. Its main focus for consultations is to enable the organizations to maintain operations and quality with as little internal disruption as possible. QuA Vodis has experience working with products such as sterile injectibles, radiopharmaceuticals, and blood and tissue products.

Glycotex wants to see such creatures as ulcers, bed sores, and sunburns put on the Australian endangered species list. The biopharmaceutical company researches and develops products based on molecular glucan receptors that trigger the healing process. Connective tissue repair, skin ulcers, and bone fractures are primary recovery fields for its glucan receptor products. Glycotex's lead product candidate, MG3601, is a topical treatment for ulcers, and it has completed Phase II clinical trials. Other therapeutic candidates include Glucocol and Glucoprime, active ingredients designed to treat tendon regeneration and topical needs, respectively. Its parent company, Novogen, owns 84% of Glycotex.

Ono Pharmaceutical traces its history back to 1717, though it took its current form in 1947. Ono Pharmaceutical Co., Ltd. is a Japan-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company offers oral medication for the treatment of bronchial asthma, disturbances of peripheral circulation, chronic pancreatitis and overactive bladder, as well as injection drugs for the treatment of acute lung injury, generalized intravascular coagulation syndrome, acute phase cerebral thrombosis and blood pressure regulators used during surgical operations. The Company has four subsidiaries and two associated companies.

DiagnoCure Inc. company was founded in 1994 and is headquartered in Quebec City, Canada. DiagnoCure, Inc., a life sciences company, engages in the research, development, production, and commercialization of diagnostic tests for the detection and management of cancers in Canada. It focuses on colon, prostate, breast, and lung cancers. The company provides ImmunoCyt /uCyt+, a tool for the diagnosis and monitoring of bladder cancer; uPM3, a noninvasive test for the detection of prostate cancer; and molecular diagnostic tests for lung cancer. It also offers Previstage GCC colorectal cancer staging test for the management of colorectal cancer. The company holds worldwide diagnostic and therapeutic rights for the use of the PCA3 technology in prostate cancer diagnosis. DiagnoCure has a strategic alliance with Gen-Probe Incorporated for the development and commercialization of diagnostic products using the DiagnoCure PCA3 gene technology for prostate cancer.

Boiron believes in nature's cures. The company makes homeopathic remedies to combat such maladies as colds, the flu, allergies, and anxiety. Founded in 1911, it is one of the oldest and largest such firms in Europe. It dominates its home market of France and also operates in Africa, Australia, North and South America, and the Middle East through about 20 subsidiaries. Along with homeopathic remedies, Boiron develops personal, animal care, and nutritional products for sale in some markets, including France (but not the US). One of the company's key products is Oscillococcinum six-dose homeopathic flu medicine. Used throughout the world, Oscillo is one of the largest homeopathic flu medicines in the US.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.